Moore et al. demonstrated that BAL1 and BAL2 are upregulated in pancreatic cancer cells, where they increase NAD(H) consumption via the type I interferon signaling pathway, thereby enhancing the sensitivity of pancreatic cancer cells to nicotinamide phosphoribosyltransferase inhibition [16]. The gene discussed is PARP9; the disease is pancreatic neoplasm.